Aller au contenu principal
Accès ouvert déclaré 2025 article

Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial

3Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : us, es. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

PURPOSE: The impact of preoperative radiation therapy (RT) on early-stage breast cancer (BC) is underexplored but may significantly improve outcomes and offer new therapeutic strategies. The YOUNGSTER study aimed to characterize the molecular changes induced by preoperative RT across BC subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and basal-like. METHODS AND MATERIALS: This exploratory study enrolled 20 patients with early-stage BC who were eligible for breast-conserving surgery and had not received prior treatment. Biological changes were assessed between baseline, 3 to 5 days post-RT, and surgical samples. A preoperative RT boost (5 × 2.67 Gy/fraction) was administered, followed by a core needle biopsy. Patients then proceeded to either surgery 4 weeks (2-8 weeks) after RT or neoadjuvant therapy. Gene expression was analyzed using a 192-gene panel, alongside immunohistochemistry for Ki67 and CD68, tumor-infiltrating lymphocytes quantification, and γH2AX staining for DNA damage assessment. RESULTS: At baseline, PAM50 subtype distribution was luminal A (35%), luminal B (25%), HER2-enriched (20%), and basal-like (20%). Early post-RT samples showed significant downregulation of proliferation genes, PAM50 proliferation signature, and Ki67 immunohistochemistry staining, increased DNA damage, and macrophage marker upregulation. In primary surgery samples (2-8 weeks post-RT) (n = 13), adaptive immune markers showed significant upregulation, along with a 14-gene immunoglobulin signature increase. CONCLUSIONS: Preoperative RT induces early and late biological changes in BC, with initial effects on proliferation reduction and DNA damage within days, followed by adaptive immune activation within weeks. RT may serve as an effective primer for immunotherapy, especially in higher-risk subtypes, supporting the potential for combinatorial approaches in BC management.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial
Date Crossref
01/01/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Breast Cancer Treatment StudiesCancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease Prognosis

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.